Pain at 6 months or more; all doses Assessed by change from baseline, using a 0‐ to 100‐mm VAS, where higher scores indicate more pain) · people with diabetic peripheral neuropathy
1 finding from 1 review
Impairment of sensation Assessed by quantitative sensory testing ‐ thermal threshold ‐ at 6 months or more · the treatment of diabetic peripheral neuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptom quality and severity Assessed by NSS score (range of possible scores 0 to 9; higher scores indicate more symptoms) · the treatment of diabetic peripheral neuropathy
1 finding from 1 review
Adverse events · the treatment of diabetic peripheral neuropathy
Acetyl‐L‐carnitine showed no clear difference in adverse events compared with methylcobalamin (low certainty).
1 finding from 1 review
Functional impairment and disability Assessed by NIS or NDS at 6 months or more · people with diabetic peripheral neuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Impairment of sensation Assessed by quantitative sensory testing ‐ vibration perception threshold ‐ at 6 months or more · people with diabetic peripheral neuropathy
1 finding from 1 review
Impairment of sensation Assessed by quantitative sensory testing ‐ thermal threshold ‐ at 6 months or more · people with diabetic peripheral neuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptom quality and severity Assessed by change in symptom score on a validated screening questionnaire (NSS or MNSI) at 6 months or more · people with diabetic peripheral neuropathy
1 finding from 1 review
no estimate extracted
2 participants
GRADE not reported
Adverse events: any adverse event, adverse events requiring withdrawal, and serious adverse events · people with diabetic peripheral neuropathy
1 finding from 1 review
Pain at 6 months or more · the treatment of diabetic peripheral neuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Functional impairment and disability Assessed by change in NDS score (range of possible scores from 0 (normal function) to 10 (maximal disability) · the treatment of diabetic peripheral neuropathy
1 finding from 1 review
Impairment of sensation Assessed by quantitative sensory testing ‐ vibration perception threshold ‐ at 6 months or more · the treatment of diabetic peripheral neuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in disability score · non‐ambulatory children with SMA types II and III
1 finding from 1 review
Muscle strength · non‐ambulatory children with SMA types II and III
1 finding from 1 review
Acquiring the ability to stand or walk · non‐ambulatory children with SMA types II and III
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in quality of life · non‐ambulatory children with SMA types II and III
1 finding from 1 review
Change in pulmonary function · non‐ambulatory children with SMA types II and III
1 finding from 1 review
Time from beginning of treatment until death or full‐time ventilation · non‐ambulatory children with SMA types II and III
1 finding from 1 review
Adverse events related to treatment · non‐ambulatory children with SMA types II and III
Oral valproic acid plus acetyl‐L‐carnitine showed no clear difference in adverse events related to treatment compared with placebo (moderate certainty).
1 finding from 1 review